PhaSeal is a containment system designed to ensure the safe preparation and administration of cytostatic drugs and thus reduce environmental contamination to work areas and to medical and support staff. The PhaSeal system was tested in an outpatient setting in Sweden for 1 year during the preparation and administration of cyclophosphamide, fluorouracil, and similar cytostatic drugs. The study was designed to determine the effectiveness of PhaSeal in preventing the leakage of cytostatic drugs frequently reported in a number of studies. Cytostatic drugs were prepared and administered using standard safety procedures, except that a biological safety cabinet was not used. At the conclusion of the study period, environmental contamination was determined from wiping samples of objects and surfaces in the drug preparation room. Neither cyclophosphamide nor fluorouracil was found in any of these samples. Results show that use of the PhaSeal system alone is sufficient to prevent environmental contamination during the preparation of cytostatic drugs.
International Agency for Research on Cancer.IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Vol. 26. Some Antineoplastic and Immunosuppressive Agents. Lyon, France: IARC; 1981.
7.
International Agency for Research on Cancer.IARC Scientific publications. No. 78. Carcinogenicity of Alkylating Cytostatic Drugs.Lyon, France: IARC; 1986.
8.
International Agency for Research on Cancer.IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Suppl. 7. Lyon, France: IARC; 1987.
9.
International Agency for Research on Cancer.IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 50. Pharmaceutical Drugs. Lyon, France: IARC; 1990.
10.
BakerG.L., KahlL.E., ZeeB.C.Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: Long-term case-control follow-up study. Am J Med.1987; 83: 1–9.
11.
GreeneM.H., HarrisE.L., GershensonD.M.Melphalan may be a more potent leukomogen than cyclophosphamide. Ann Intern Med.1986; 105: 360–7.
12.
HemminkiK., KyyönenP., LindbohmM-LSpontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health.1985; 39: 141–7.
13.
SelevanS.G., LindbohmM-L, HornungR.W.A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med.1985; 313: 1173–8.
14.
ValanisB.G., VollmerW.M., LabuhnK.T.Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm.1993; 50: 455–62.
15.
ValanisB.G., VollmerW.M., LabuhnK.T.Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs.1993; 16: 288–95.
16.
ValanisB., VollmerW., LabuhnK.Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med.1997; 39: 574–80.
17.
SkovT., MaarupB., OlsenJ.Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med.1992; 49: 855–61.
18.
Provisions issued by the National Board of Occupational Safety and Health [in Swedish]. Cytostatics.1984: 8. Solna, Sweden.
19.
U.S. Department of Labor.1986. Guidelines for cytotoxic (antineoplastic) drugs (Pub 8-1.1).OSHA, Office of Occupational Medicine; January, 1986.
20.
American Society of Hospital Pharmacists.ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm.1990; 47: 1033–49.
21.
SkovT.Handling antineoplastic drugs in the European Community countries. Eur J Cancer Prev.1993; 2: 43–46.
22.
Oncology Nursing Society.Cancer Chemotherapy Guidelines on Recommendations for Practice.Pittsburgh., PA: Oncology Nursing Press, Inc; 1996.
23.
Comprehensive Cancer Centres. Workbook: Cytostatic Drugs. [in Dutch].Utrecht, The Netherlands; 1997.
24.
HirstM., TseS., MillsD.G.Occupational exposure to cyclophosphamide. Lancet.1984; 1: 186–8.
25.
EveloC.T.A., BosR.P., PetersJ.G.P.Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health.1986; 58: 151–55.
26.
EnsslinA.S., StollY., PethranA.Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med.1994; 51: 229–33.
27.
EnsslinA.S., HuberR., PethranA.Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: Urinary excretion and cytogenetics studies. Int Arch Occup Environ Health.1997; 70: 205–8.
28.
SessinkP.J.M., BoerK.A., ScheefhalsA.P.H.Occupational exposure to antineoplastic agents at several departments in a hospital: Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health.1992; 64: 105–12.
29.
SessinkP.J.M., ScholtesM.M., AnzionR.B.M.Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr.1993; 616: 333–7.
30.
SessinkP.J.M., van de KerkhofM.C.A., AnzionR.B.M.Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route?Arch Environ Health.1994; 49: 165–9.
31.
SessinkP.J.M., CernM., RössnerP.Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res.1994; 309: 193–9.
32.
SessinkP.J.M., KroeseE.D., van KranenH.J.Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health.1995; 67: 317–23.
33.
SessinkP.J.M., WittenhorstB.C.J., AnzionR.B.M.Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch Environ Health.1997; 52: 240–4.
